Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04671251 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Avalo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04671251: Completed Phase 1 study, sponsored by Avalo Therapeutics.
NCT04671251 is a Phase 1 study that has completed, run by Avalo Therapeutics. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04671251, a Phase 1 study, has completed, sponsored by Avalo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
Primary Outcome
Identify the recommended Phase 2 dose based on safety, pharmacokinetics and pharmacodynamics observed in this Phase 1b study.
Interventions
- DRUG AEVI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
What the finished NCT04671251 record still lists
NCT04671251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which AEVI-007 is the first listed.
NCT04671251 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04671251 about?
NCT04671251 is a clinical study titled "Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma". This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
What is the current status of trial NCT04671251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-12-15. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04671251?
The interventions under investigation include: AEVI-007 (DRUG).
Who is sponsoring clinical trial NCT04671251?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04671251's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI